Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Astellas Pharma Inc.Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer – – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions – TOKYO, Oct. 6, 2026 -- Astellas Pharma Inc....
- Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supplyCollaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York
- National Organization for Rare Disorders (NORD®)CNBC's Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD Breakthrough SummitBioMarin, Jazz Pharmaceuticals, and Otsuka CEOs to Join NORD CEO to Examine What it Takes to Turn Scientific Advancements into Patient Progress — The National Organization for Rare Disorders (NORD®) today announced that CNBC "Squawk Box" co-anchor...
- Alvotech semur við LOTTE Biologics í Syracuse í Bandaríkjunum um framleiðslu á líftæknilyfjahliðstæðum og eykur þannig framleiðslugetu sínaREYKJAVÍK, Ísland, og SEÚL, Suður-Kórea (6. október 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB) og LOTTE Biologics tilkynntu í dag langtímasamstarf um framleiðslu líftæknilyfjahliðstæðna. Samstarfið er liður í uppbyggingu alþjóðlegrar framleiðslu Alvotech. Alvotech er alþjóðlegt líftæknifyrirtæki sem sérhæfir sig í þróun og framleiðslu slíkra lyfja fyrir sjúklinga um allan heim. LOTTE Biologics sérhæfir sig í framleiðslu á líftæknilyfjum.
- National Comprehensive Cancer NetworkCancer Prevention and Screening Takes Center Stage During D.C. Summit Convened by NCCNNational Comprehensive Cancer Network Oncology Policy Summit featured leading voices from NCI, CDC, and more. — The National Comprehensive Cancer Network® (NCCN®) hosted a two-day summit focused on expanding access to life-saving cancer prevention...
- Faruqi & Faruqi LLPUNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -...
- ComplianceQuestComplianceQuest and Zolon PCS Selected to Modernize U.S. Food and Drug Administration (FDA) Enterprise Quality Management SystemTAMPA, FLA., Oct 7, 2026 - ComplianceQuest, a leading provider of AI-powered connected Quality, Risk and Compliance (QRC) systems, and Zolon PCS, a provider of secure, mission-focused IT services to federal agencies, today announced that the U.S. Food and Drug Administration (FDA) will modernize its enterprise quality management operations on the ComplianceQuest platform. The initiative will be delivered under the FDA Cloud Quality Management System Blanket Purchase Agreement (BPA), a five-year agreement awarded to Zolon PCS as prime contractor, with ComplianceQuest as its platform partner. Together, ComplianceQuest and Zolon PCS will help FDA implement a modern, secure, AI-enabled quality management solution built on the Salesforce FedRAMP Government Cloud platform. The solution is designed to strengthen compliance, improve consistency, streamline quality processes, and deliver greater insight across FDA's centers and offices. The initiative will focus on four priorities: Connected Quality Operations: Bringing document control, training, change, CAPA, audits, other key processes coupled with reporting to support consistent execution across the sites, functions, and organizational units. Trusted Data and Enterprise Visibility: Creating a centralized foundation for quality, risk and compliance data with end-to-end traceability and real-time insight across the agency. Intelligence and Automation: Applying AI and intelligent automation to accelerate investigations, surface relevant insights, identify emerging risks, and support better decisions. Secure, Scalable Federal Delivery: Combining a platform built to support large user populations, growing data volumes, and evolving regulatory requirements with Zolon PCS's federal expertise in cloud, cybersecurity, systems integration, and agile delivery. The FDA initiative reflects a broader shift across regulated environments. As operational complexity, regulatory expectations, and quality data volumes grow, organizations are moving beyond individual quality processes toward connected, enterprise-wide approaches. ComplianceQuest's QRC platform is built for this model, unifying Quality, Risk and Compliance across Product, Quality, Manufacturing, People, Suppliers, and Customers on a single, connected system. "Quality management is evolving from individual systems and processes toward connected enterprise platforms," said Prashanth Rajendran, CEO of ComplianceQuest. "We are proud to partner with Zolon PCS to support FDA's quality system modernization. This work highlights the growing need for technology that can meet the complexity, rigor, security, and evolving requirements of highly regulated environments." "We are honored by FDA's confidence in our team and proud to support its vital public health mission," said Goutham Amarneni, President of Zolon PCS. "Modernizing quality management at this scale takes both the right platform and the right delivery partner. Together with ComplianceQuest, we are bringing FDA a secure, AI-enabled solution built for the rigor of federal operations." About ComplianceQuest ComplianceQuest is the leading AI-powered Quality, Risk and Compliance (QRC) system that connects product, manufacturing, people, and partner quality in a single system. Built on Salesforce, the platform delivers end-to-end visibility, AI-driven intelligence, and enterprise-scale execution, enabling organizations to prevent risk, ensure compliance by design, and turn quality into a driver of growth. About Zolon PCS Zolon PCS, LLC is a joint venture between Pioneer Corporate Services and Zolon Tech, Inc., delivering advanced, secure, and mission-focused IT services and consulting to federal agencies. For more information, visit zolonpcs.zolontech.com. Media Contact ComplianceQuest: [email protected] | 408-458-8343 | www.compliancequest.com SOURCE: ComplianceQuest
- Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder ValueFirst Patient Dosed with JOTROL™ Marks Major Clinical Milestone for Jupiter Neurosciences’ Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL™ in Patients with Parkinson’s Disease
- Cell Therapy Packaging Market Size, Share, Trends, and Forecast, 2026-2033 | CAR-T Commercialization and Cold-Chain Investment Propel 12.0% CAGR to $1.21 BillionCAR-T commercialization, cryopreservation, strict tracking rules, and IoT-enabled cold chains drive demand for high-barrier cell therapy packaging.
- Cell Therapy Monitoring Kits Market Size, Share, Trends, and Forecast, 2026-2033 | Market to Reach $2.5 Billion as CAR-T Adoption and Regulatory Demands Drive 7.6% CAGRRising cell and gene therapy adoption, stringent quality rules, and real-time batch testing needs are driving demand for specialized monitoring kits.
- Compound Management Market Size and Share Analysis, Industry Trends, and Growth Forecasts, 2026-2031; AI-Enabled Automation and Biologics Drive 14.87% CAGR Through 2031Boost ROI by outsourcing sample archives to convert fixed costs into variable fees, while AI-enabled automation cuts discovery timelines, manual errors and reagent use.
- Orphan Drugs - Global Market Size, Share, Industry Trends, and Growth Forecasts, 2025-2031 | Biologics and Asia-Pacific Drive 6.36% CAGR to USD 334.28 BillionBoost ROI through tax credits, fee waivers, exclusivity, fast-track filings and launch sequencing; prioritize biologics, neurology and Asia-Pacific access.